Medicenna Therapeutics Corp. MDNAF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.76% | -6.67% | -18.74% | -22.54% | -22.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.23% | 10.78% | 17.14% | 15.67% | 16.25% |
| Operating Income | -3.23% | -10.78% | -17.14% | -15.67% | -16.25% |
| Income Before Tax | -41.47% | -55.07% | 52.31% | 49.25% | 51.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.47% | -55.07% | 52.31% | 49.25% | 51.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.47% | -55.07% | 52.31% | 49.25% | 51.06% |
| EBIT | -3.23% | -10.78% | -17.14% | -15.67% | -16.25% |
| EBITDA | -3.41% | -10.85% | -17.18% | -15.51% | -16.01% |
| EPS Basic | -33.06% | -42.15% | 58.51% | 55.64% | 56.69% |
| Normalized Basic EPS | -33.11% | -42.13% | 58.46% | 55.61% | 56.68% |
| EPS Diluted | -33.06% | -42.15% | 58.51% | 55.64% | 56.69% |
| Normalized Diluted EPS | -33.11% | -42.13% | 58.46% | 55.61% | 56.68% |
| Average Basic Shares Outstanding | 6.76% | 8.51% | 9.87% | 11.18% | 11.69% |
| Average Diluted Shares Outstanding | 6.76% | 8.51% | 9.87% | 11.18% | 11.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |